A pipeline for screening small molecules with growth inhibitory activity against Burkholderia cenocepacia

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Selin, Carrie ^a   Stietz, Maria S ^a   Blanchard, Jan E ^c,d   Gehrke, Sebastian S ^c   Bernard, Sylvain ^b   Hall, Dennis G ^b   Brown, Eric D ^c,d   Cardona, Silvia T ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CHLORAMPHENICOL; MEROPENEM; TETRACYCLINE; TRIMETHOPRIM; MOLECULAR LIBRARY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BIOFILM; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA INFECTION; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; ERYTHROCYTE; HEMOLYSIS; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SHEEP; TOXICITY TESTING; ANIMAL; DRUG EFFECTS; FEEDING BEHAVIOR; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MOLECULAR LIBRARY; PHARMACOLOGY; PRECLINICAL STUDY; PROCEDURES; TOXICITY;

BACTERIA (MICROORGANISMS); BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA COMPLEX; CAENORHABDITIS ELEGANS;

ANIMALS; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CENOCEPACIA; CAENORHABDITIS ELEGANS; DRUG EVALUATION, PRECLINICAL; FEEDING BEHAVIOR; HEMOLYSIS; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SHEEP; SMALL MOLECULE LIBRARIES;

EID: 84936803081     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128587     Document Type: Article

References (47)

1. Vial L, Chapalain A, Groleau MC, Deziel E. (2011) The various lifestyles of the Burkholderia cepacia complex species: a tribute to adaptation. Environ Microbiol 13: 1-12. doi: 10.1111/j.1462-2920.2010.02343.x PMID: 20880095
2. Burkholder WH. (1950) Sour skin, a bacterial rot of onion bulbs. Phytopathol 40: 115-117.
3. Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AP, Falagas ME. (2009) Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents 33: 394-404. doi: 10.1016/j.ijantimicag.2008.09.010 PMID: 19097867
4. Mahenthiralingam E, Urban TA, Goldberg JB. (2005) The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3: 144-156. PMID: 15643431
5. Valvano MA, Keith KE, Cardona ST. (2005) Survival and persistence of opportunistic Burkholderia species in host cells. Curr Opin Microbiol 8: 99-105. PMID: 15694863
6. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, et al. (2012) Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 109: 5809-5814. doi: 10.1073/pnas.1120577109 PMID: 22451929
7. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. (2001) Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153: 345-352. PMID: 11207152
8. Mc Manus TE, Moore JE, Crowe M, Dunbar K, Elborn JS. (2003) A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic Burkholderia cepacia infection. J Infect 46: 56-59. PMID: 12504610
9. Hafkin J, Blumberg E. (2009) Infections in lung transplantation: new insights. Curr Opin Organ Transplant 14: 483-487. doi: 10.1097/MOT.0b013e32833062f6 PMID: 19623072
10. Mahenthiralingam E, Baldwin A, Dowson CG. (2008) Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol 104: 1539. doi: 10.1111/j.1365-2672.2007.03706.x PMID: 18217926
11. Conway SP, Brownlee KG, Denton M, Peckham DG. (2003) Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2: 321-332. PMID: 14719998
12. Jones AM, Dodd ME, Govan JR, Barcus V, Doherty CJ, Morris J, et al. (2004) Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 59: 948-951. PMID: 15516469
13. Sass A, Marchbank A, Tullis E, Lipuma JJ, Mahenthiralingam E. (2011) Spontaneous and evolutionary changes in the antibiotic resistance of Burkholderia cenocepacia observed by global gene expression analysis. BMC Genomics 12: 373. doi: 10.1186/1471-2164-12-373 PMID: 21781329
14. Hong-Geller E, Micheva-Viteva S. (2013) Small molecule screens to identify inhibitors of infectious disease. In: Prof. Shelmy Hany El., editor. Drug Discovery.: InTech. pp. 157.
15. Ewbank JJ, Zugasti O. (2011) C. elegans: model host and tool for antimicrobial drug discovery. Dis Model Mech 4: 300-304. doi: 10.1242/dmm.006684 PMID: 21504910
16. Conery AL, Larkins-Ford J, Ausubel FM, Kirienko NV. (2014) High-throughput screening for novel antiinfectives using a C. elegans pathogenesis model. Curr Protoc Chem Biol 6: 25-37. doi: 10.1002/9780470559277.ch130160 PMID: 24652621
17. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40. PMID: 17159923
18. Pathania R, Brown ED. (2008) Small and lethal: searching for new antibacterial compounds with novel modes of action. Biochem Cell Biol 86: 111-115. doi: 10.1139/O08-011 PMID: 18443624
19. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, et al. (2009) High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89: 334-353. doi: 10.1016/j.tube.2009.05.008 PMID: 19758845
20. Galperin MY, Koonin EV. (2004) 'Conserved hypothetical' proteins: prioritization of targets for experimental study. Nucleic Acids Res. 32: 5452-5463. PMID: 15479782
21. Zhang CT, Zhang R. (2007) Gene Essentiality Analysis Based on DEG, a Database of Essential Genes. Methods Mol Biol 416: 391-400.
22. Joyce AR, Palsson BO. (2008) Predicting gene essentiality using genome-scale in silico models. Methods Mol Biol 416: 433-457. doi: 10.1007/978-1-59745-321-9-30 PMID: 18392986
23. Pathania R, Zlitni S, Barker C, Das R, Gerritsma DA, Lebert J, et al. (2009) Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat Chem Biol 5: 849-856. doi: 10.1038/nchembio.221 PMID: 19783991
24. Brown ED, Thomas DY. (2008) Canadian Chemical Biology Network: biochemistry back to the future. Biochem Cell Biol 86: ix, xi-xii. doi: 10.1139/o08-903 PMID: 18509890
25. Mahenthiralingam E, Coenye T, Chung JW, Speert DP, Govan JR, Taylor P, et al. (2000) Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol 38: 910-913. PMID: 10655415
26. Coenye T, Vandamme P, LiPuma JJ, Govan JR, Mahenthiralingam E. (2003) Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol 41: 2797-2798. PMID: 12791937
27. Holloway BW, Romling U, Tummler B. (1994) Genomic mapping of Pseudomonas aeruginosa PAO. Microbiology 140: 2907-2929. PMID: 7812433
28. Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, Ausubel FM. (2006) Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A 103: 10414-10419. PMID: 16801562
29. Brenner S. (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71-94. PMID: 4366476
30. Zhang JH, Chung TD, Oldenburg KR. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73. PMID: 10838414
31. Brideau C, Gunter B, Pikounis B, Liaw A. (2003) Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8: 634-647. PMID: 14711389
32. Wikler M, Cockerill F, Bush K, Dudley M, Eliopoulos GM, Hardy D, et al. (2008) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 29: 1-10.
33. Peeters E, Nelis HJ, Coenye T. (2009) In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. J Antimicrob Chemother 64: 801-809. doi: 10.1093/jac/dkp253 PMID: 19633000
34. Strom MB, Haug BE, Skar ML, Stensen W, Stiberg T, Svendsen JS. (2003) The pharmacophore of short cationic antibacterial peptides. J Med Chem 46: 1567-1570. PMID: 12699374
35. Sperandio D, Rossignol G, Guerillon J, Connil N, Orange N, Feuilloley MG, et al. (2010) Cell-associated hemolysis activity in the clinical strain of Pseudomonas fluorescens MFN1032. BMC Microbiol 10: 124-2180-10-124.
36. Kaplan JB, Lovetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S, et al. (2011) Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo) 65: 73-77.
37. Li X, Zolli-Juran M, Cechetto JD, Daigle DM, Wright GD, Brown ED. (2004) Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem Biol 11: 1423-1430. PMID: 15489169
38. Ulaczyk-Lesanko A, Pelletier E, Lee M, Prinz H, Waldmann H, Hall DG. (2007) Optimization of three- and four-component reactions for polysubstituted piperidines: application to the synthesis and preliminary biological screening of a prototype library. J Comb Chem 9: 695-703. PMID: 17521171
39. Bolton E, Wang Y, Thiessen PA, Bryant SH. (2008) PubChem: Integrated platform of small molecules and biological activities. In: Anonymous Annual Reports in Computational Chemistry. Oxford, UK: Elsevier. pp. 217-240.
40. Wang Y, Suzek T, Zhang J, Wang J, He S, Cheng T, et al. (2014) PubChem BioAssay: 2014 update. Nucleic Acids Res 42: D1075-82. doi: 10.1093/nar/gkt978 PMID: 24198245
41. Balakin KV, Ivanenkov YA, Skorenko AV, Nikolsky YV, Savchuk NP, Ivashchenko AA. (2004) In silico estimation of DMSO solubility of organic compounds for bioscreening. J Biomol Screen 9: 22-31. PMID: 15006145
42. Di L, Kerns EH. (2006) Biological assay challenges from compound solubility: strategies for bioassay optimization. Drug Discov Today 11: 446-451. PMID: 16635808
43. Oldenburg K, Pooler D, Scudder K, Lipinski C, Kelly M. (2005) High throughput sonication: evaluation for compound solubilization. Comb Chem High Throughput Screen 8: 499-512. PMID: 16178809
44. Richards JJ, Reyes S, Stowe SD, Tucker AT, Ballard TE, Mathies LD, et al. (2009) Amide isosteres of oroidin: assessment of antibiofilm activity and C. elegans toxicity. J Med Chem 52: 4582-4585. doi: 10.1021/jm900378s PMID: 19719234
45. Stowe SD, Tucker AT, Thompson R, Piper A, Richards JJ, Rogers SA, et al. (2012) Evaluation of the toxicity of 2-aminoimidazole antibiofilm agents using both cellular and model organism systems. Drug Chem Toxicol 35: 310-315. doi: 10.3109/01480545.2011.614620 PMID: 22292413
46. Valko K, Butler J, Eddershaw P. (2013) Predictive approaches to increase absorption of compounds during lead optimisation. Expert Opin Drug Discov 8: 1225-1238. doi: 10.1517/17460441.2013.815613 PMID: 23865945
47. Breger J, Fuchs BB, Aperis G, Moy TI, Ausubel FM, Mylonakis E. (2007) Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 3: e18. PMID: 17274686